24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Diabetes
Resources
Basic InformationLatest News
Diabetes Raises Heart Failure Risk More in Women Than MenCan You Live Well With Type 1 Diabetes for 81 Years? Just Ask Don RayEasing Depression Can Bring Longer Life to People With DiabetesMedtronic Recalls Some Insulin Pumps as FDA Warns They Could Be HackedFDA Approves Victoza Injection for Children 10 Years and OlderCommon Infant Vaccine May Also Shield Kids From Type 1 DiabetesType 1 Diabetes Might Affect Young Kids' Brain DevelopmentDrug May Help Delay Onset of Type 1 DiabetesVitamin D Supplements Don't Prevent Type 2 Diabetes: StudyWhat and How You Eat Affects Your Odds for Type 2 DiabetesAHA News: Diabetes and Heart Failure Are Linked; Treatment Should Be TooMidlife Diabetes Can Really Raise Your Odds for Stroke Years LaterTight Diabetes Control Alone May Not Benefit the Heart Long-TermOpen Communication Helps Teens Manage Type 1 DiabetesNew Gene Variants for Type 2 Diabetes FoundPost-Hospital Low Blood Sugar a Danger to DiabeticsAHA News: Why Are Women With Diabetes at Greater Risk for Poor Heart Health?Newer Diabetes Drugs Linked to 'Flesh-Eating' Genital InfectionAHA News: Study Backs Lower Blood Pressure Target for People With DiabetesNewer Diabetes Drug Shows Promise in Kids, TeensNo 'One-Size-Fits-All' Diet for Diabetics, Expert Panel SaysMicrobes in Diabetic Foot Ulcers May Help Predict Treatment SuccessCommon Diabetes Drug May Also Shield Kidneys, HeartThe Earlier You Develop Type 2 Diabetes, the Greater Your Heart RisksHigh Insulin Costs Come Under Fire on Capitol HillType 1 Diabetics Often Unaware of Low Blood Sugar EpisodesCommon Diabetes Test May Often Miss the MarkHealth Tip: Reading Food Labels for DiabeticsWhich Type of Exercise Might Lower Your Diabetes Risk?First Steps After a Diabetes DiagnosisCoping With Diabetes Is a Family AffairAHA News: Diabetes Remains Dangerous Despite Modern MedicineWalnuts, Almonds Help the Hearts of Those With Type 2 DiabetesFirst Customizable Insulin Pump ApprovedContinuous Glucose Monitors Make Managing Diabetes EasierWeight-Loss Surgery Typically Pushes Type 2 Diabetes Into RemissionHigh-Tech Capsule Could One Day Replace Insulin InjectionsWhat Illness Lands the Most Seniors in the ER?Diabetic Crisis? 'Wonder Dog' Emma Alerts Owner to the DangerEating Before Bedtime Won't Send Blood Sugar Levels SoaringStudy Examines Link Between Type 1 Diabetes, Broken BonesExperimental Drug Could Be New Option for Type 2 DiabetesHeart-Healthy Living Also Wards Off Type 2 DiabetesType 2 Diabetes Before 40 Tied to Mental Illness HospitalizationsStudy Eases Concern That Common Diabetes Med Might Harm BonesIf You're Diabetic, Foot Care a MustDo Your Gut Bacteria Affect Your Diabetes Meds?Some Diabetes Drugs Linked to Higher Heart RisksScientists Get Closer to Generating Cells Lost to DiabetesMigraine's 'Silver Lining': Lowered Risk for Diabetes?
Links
Related Topics

Medical Disorders

FDA Approves Victoza Injection for Children 10 Years and Older


HealthDay News
Updated: Jun 18th 2019

new article illustration

TUESDAY, June 18, 2019 (HealthDay News) -- Victoza (liraglutide) injection is now approved to treat type 2 diabetes in children 10 years and older, the U.S. Food and Drug Administration announced.

Approved to treat type 2 diabetes in adults in 2010, Victoza is the first noninsulin drug to be approved to treat type 2 diabetes in children since metformin in 2000. Victoza's labeling states that the injection is not a substitute for insulin and is not indicated for patients with type 1 diabetes or those with diabetic ketoacidosis. Dosage of Victoza in children should start at 0.6 mg daily for at least one week. The manufacturer's prescribing information indicates that if additional glycemic control is required, the dose should be increased to 1.2 mg daily, and then to 1.8 mg daily after at least one week of treatment with the 1.2-mg daily dose if additional control is still required.

Approval of Victoza in children aged 10 years and older was based on several placebo-controlled trials in adults and one placebo-controlled trial in children. In the trial of 134 children aged 10 years and older, at 26-week follow-up, HbA1c levels reduced to less than 7 percent for approximately 64 percent of children treated with Victoza compared with 37 percent of children treated with placebo. Researchers found similar results when patients were also taking insulin simultaneously.

Although Victoza has been indicated to reduce the risk for major adverse cardiovascular events in adults with type 2 diabetes, the FDA notes that the drug's effect on major adverse cardiovascular events in children has not been studied, and it is therefore not indicated to reduce the risk for these events in children. Children aged 10 years and older who are taking Victoza have an increased risk for hypoglycemia even without additional therapies for diabetes. Due to an increased risk for thyroid C-cell tumors, Victoza is contraindicated in patients who have had medullary thyroid carcinoma, those with family members who have had medullary thyroid carcinoma, and patients with multiple endocrine neoplasia syndrome type 2.

Approval of Victoza was granted to Novo Nordisk.

More Information